Citigroup
DRUG

Citigroup’s Bright Minds Biosciences DRUG Stock Holding History

Citigroup’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
3,612
+3,315
+1,116% +$260K ﹤0.01% 4212
2026
Q1 		$21.6K Buy
297
+183
+161% +$14.7K ﹤0.01% 4801
2025
Q4 		$9.18K Sell
114
-81
-42% -$5.41K ﹤0.01% 5088
2025
Q3 		$11.8K Sell
195
-1,437
-88% -$55.8K ﹤0.01% 4967
2025
Q2 		$43.1K Buy
1,632
+1,631
+163,100% +$48.9K ﹤0.01% 4843
2025
Q1 		$36 Hold
1
– – ﹤0.01% 5460
2024
Q4 		$36 Buy
+1
New +$35 ﹤0.01% 5728

Other funds holding DRUG

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Citigroup's DRUG Position: Q2 2026 in Review

Citigroup increased its Bright Minds Biosciences (DRUG) stake by 1,116% in Q2 2026, buying an estimated $260K and bringing the position to 3,612 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #4212.

Citigroup first reported a position in DRUG in Q4 2024 and has held it in 7 quarters since. 11 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Citigroup held 3,612 shares of Bright Minds Biosciences worth $260K as of Q2 2026.
  • Citigroup bought 3,315 Bright Minds Biosciences shares in Q2 2026, an estimated $260K.
  • Bright Minds Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4212 holding.
  • Citigroup first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 11 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.